Related Experiment Videos
Preclinical evaluation of new taxoids
1Pathology and In Vivo Models, Oncology Disease Group, Aventis Pharma Group, Aventis Pharma S.A., 13, quai Jules Guesde, Vitry-sur-Seine, F-94403, France. marie-christine.bissery@aventis.com
Abstract:
Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers. A number of taxoids have then been synthesized in an effort to improve some of the features of the existing drugs. Although the literature is still scant of preclinical data due to the highly competitive field, several compounds are already in clinical trials. Most of these will be reviewed and have, either improved water solubility or reduced cross-resistance with marketed taxoids or reduced interaction with P-glycoprotein. In addition, the reduced recognition of several compounds by multi-drug-resistance related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity. It is likely that these additional properties should lead to an expanded spectrum of clinical activity compared to that of clinically available taxoids.
Insights
New taxoid cancer drugs show promise with improved properties like better solubility and oral availability. These advancements may expand their clinical use beyond current taxoids in treating various cancers.
Area of Science:
- Oncology
- Pharmacology
Background:
- Paclitaxel and docetaxel are established cancer treatments, particularly for breast, lung, and ovarian cancers.
- Ongoing research focuses on synthesizing novel taxoids to overcome limitations of existing drugs.
Purpose of the Study:
- To review newly synthesized taxoids and their preclinical data.
- To highlight improvements in water solubility, reduced cross-resistance, and P-glycoprotein interaction.
Main Methods:
- Review of preclinical data for novel taxoid compounds.
- Analysis of drug properties including solubility, resistance profiles, and bioavailability.
Main Results:
- Several new taxoids demonstrate improved water solubility and reduced cross-resistance.
- Some compounds show reduced interaction with P-glycoprotein and enhanced oral bioavailability.
- These taxoids exhibit significant in vivo antitumor activity.
Conclusions:
- Novel taxoids possess enhanced properties compared to existing treatments.
- Improved characteristics suggest a broader clinical activity spectrum for these new agents.